

REGRILIN[®]
(Eptifibatide) Injection

www.tajpharma.com



REGRILIN[®] (Eptifibatide) Injection

REGRILIN[®] (eptifibatide) injection is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI)

Indications for REGRILIN[®] Injection

To decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI)

To decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting

Selected Safety Information

REGRILIN[®] Is Contraindicated in Patients With:

A history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days

Severe hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) not adequately controlled on antihypertensive therapy

Major surgery within preceding 6 weeks

History of stroke within 30 days or any history of hemorrhagic stroke

Current or planned administration of another parenteral GP IIb/IIIa inhibitor

Dependency on renal dialysis

Hypersensitivity to REGRILIN[®] (eptifibatide) Injection or any component of the product

(hypersensitivity reactions that occurred included anaphylaxis and urticaria)